What is the role of front-line bevacizumab?

Bevacizumab is a drug that inhibits growth of blood vessels that cancers need to support their growth, thus preventing the growth of cancer cells.

Previously-untreated patients must be carefully selected when considering the use of bevacizumab. Bevacizumab is only recommended for patients with these features:

Stage 4 cancer

Presence of tumours after surgical removal instead of all cancerous tissue being successfully removed

Bevacizumab is recommended to be given with paclitaxel and carboplatin for 1 year. Paclitaxel belongs to the taxane family of drugs that inhibit cancer growth. Carboplatin is a drug used to treat cancer cells by disrupting cell growth of cancer cells.

The preferred dose of bevacizumab is 7.5 mg/kg.